4CPS-230 Time course of hypercholesterolaemia treatment with PCSK9 inhibitors monoclonal antibodies (iPCSK9)
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Monoclonal antibodies directed against the PCSK9 protein revolutionised the treatment for hypercholesterolaemia 5 years ago. It is necessary to review the effectiveness data over time in real clinical practice. Aim and Objectives To find out the evolution over time of the effectiveness of hypercholesterolaemia treatment with iPCSK9 (alirocumab/evolocumab). Material and Methods Observational, retrospective, analytical and descriptive study in a second-level hospital including patients diagnosed with hypercholesterolaemia who started iPCSK9 treatment from September 2017 to March 2023. Inclusion criteria: age>18 years, on treatment for at least 12 months with alirocumab (75mg/14 days or 150 mg/28 days) and evolocumab (140 mg/14 days). Intensification dosing was alirocumab 150 mg/14 days. Efficacy variables were collected: baseline LDL value (LDLb), LDL at 1/3/6/12 months, target LDL, dates of: start/end of treatment, change of dosage, reaching target (100/70/70/55mg/dL according to patient need), reaching 50% LDLb reduction. The data were obtained from the patient‘s clinical history and the electronic dispensing register. Statistical analysis was performed with STATA software using Kaplan-Meier curve analysis and Mantel-Haenszel test. Results Forty patients were included, 50% were treated with alirocumab 75mg/14 days, 22.5% with alirocumab 150 mg/28days and 27.5% with evolocumab 140 mg/14 days. Finally, at 14 months, at least 50% of patients needed to intensify alirocumab dosing. Comparing both starting doses of alirocumab, it was observed that the median time to intensification was 7 months with 75mg/14 days dose, while it was 33 months with the monthly dose (150 mg/month) (p=0.02). Conclusion and Relevance IPCSK9 have proven to be effective drugs in a short period of time for the treatment of hypercholesterolaemia, with 50% of patients reaching target LDL levels within 6 months. Those patients on alirocumab treatment have on average needed to intensify dosing in just over a year, however the baseline dose(150mg/month) has been proven more effective over time. Evolocumab seems to be faster in achieving the 50% of LDL reduction. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: C Mayo, V Collados Arroyo, A Henares López, L Carrasco Piernavieja, R Fernandez Caballero
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408376292